<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01958229</url>
  </required_header>
  <id_info>
    <org_study_id>200910027M</org_study_id>
    <nct_id>NCT01958229</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Telbivudine in Chronic Hepatitis B Patients</brief_title>
  <official_title>A Multicenter Open-label, Observational Study of Telbivudine Treatment Outcome in Patients With Chronic B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to support the optimal use of telbivudine by providing data to refine&#xD;
      our understanding of telbivudine efficacy and resistance in real life clinical setting in&#xD;
      patients with chronic hepatitis B with defined baseline characteristics and 24-week PCR&#xD;
      negativity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be multicenter, open-label and observational data collection of patients on&#xD;
      telbivudine who meet baseline characteristics defined as the majority of patients seen in the&#xD;
      clinic setting. Data collection will take place after enrollment, at Week 12, 24, 52, 76 and&#xD;
      104 for efficacy assessments. In patients who discontinue observational drug earlier,&#xD;
      clinical information would be kept following for assessment as well.&#xD;
&#xD;
      Study purpose:&#xD;
&#xD;
      This study is designed to evaluate the efficacy of telbivudine in real-life clinical settings&#xD;
      with the use of the Roadmap Concept in chronic hepatitis B treatment.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Primary:&#xD;
&#xD;
      To observe telbivudine's 2-year efficacy in real-world clinical setting of achieving HBV-DNA&#xD;
      &lt; 60 IU/ml and HBeAg seroconversion rate in patients with defined baseline characteristics&#xD;
      and 24-week treatment PCR negativity as previously reported in GLOBE study's sub-analysis.&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
        1. To observe the treatment outcomes.&#xD;
&#xD;
        2. To validate the result of super-responder trial.&#xD;
&#xD;
        3. To validate the Roadmap Concept.&#xD;
&#xD;
      Population:&#xD;
&#xD;
      The study population will consist of a representative group of 500 chronic hepatitis B&#xD;
      patients with detectable HBsAg for more than 6 months who need telbivudine therapy based on&#xD;
      investigators' judgment in 16 medical centers located in Taiwan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PCR negativity</measure>
    <time_frame>week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PCR negativity</measure>
    <time_frame>week 104</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HBeAg seroconversion rate</measure>
    <time_frame>week 104</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of ALT normalization</measure>
    <time_frame>week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic resistance</measure>
    <time_frame>week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ALT normalization</measure>
    <time_frame>week 104</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotypic resistance</measure>
    <time_frame>week 104</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">23</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <condition>Roadmap Concept in Chronic Hepatitis B Treatment</condition>
  <condition>24-week PCR Negativity of Telbivudine</condition>
  <condition>PCR Negativity at 52 and 104 Week</condition>
  <condition>HBeAg Seroconversion Rate at 52 and 104 Week</condition>
  <arm_group>
    <arm_group_label>CHB patients without cirrhosis</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      10 c.c whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis B patients without cirrhosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female 18 to 65 years of age&#xD;
&#xD;
          -  Documented chronic hepatitis B defined by ALL of following:&#xD;
&#xD;
               1. Clinical history compatible with compensated chronic hepatitis B&#xD;
&#xD;
               2. Detectable serum hepatitis B surface antigen (HBsAg)&gt; 6 months and at the&#xD;
                  screening visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
&#xD;
          -  co-infection with hepatitis C virus (HCV) or HIV&#xD;
&#xD;
          -  Clinical or imaging diagnosis of cirrhosis&#xD;
&#xD;
          -  Evidence of decreased renal function of creatinine &gt;(=)2x ULN&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Horng Kao, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei City</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 1, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2013</study_first_posted>
  <last_update_submitted>October 8, 2013</last_update_submitted>
  <last_update_submitted_qc>October 8, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

